17-Nov-2026 18:47:35
LAURUS LABS : PROMOTERS SOLD 20.70 LAKH SHARES
• Dr Satyanarayana Chava sold 15,70,000 equity shares across November 11 and 12, 2026 • V V Ravi Kumar sold 5,00,000 equity shares across the same two days • T…
Latest market headlines for LAURUSLABS on Terminal.
17-Nov-2026 18:47:35
• Dr Satyanarayana Chava sold 15,70,000 equity shares across November 11 and 12, 2026 • V V Ravi Kumar sold 5,00,000 equity shares across the same two days • T…
17-Nov-2026 14:54:10
LAURUS LABS says Most Revenue Comes From Big Pharma Clients In CDMO
17-Nov-2026 12:24:08
LAURUS LABS says Don't See Any Reduction In Return Ratios | Promoters Have No Plan For Further Stake Sale
17-Nov-2026 12:23:22
LAURUS LABS says Capex Will Be Funded Via Internal Accruals | Gross & EBITDA Margins Will Continue To Remain At Similar Lvls For The Next Few Qtrs
17-Nov-2026 12:23:05
LAURUS LABS SAYS NO PLAN TO SELL FURTHER STAKE
16-Nov-2026 11:39:16
Business outlook remains unchanged 5% decline in the stock price is providing a good opportunity to buy
30-Oct-2026 09:47:13
LAURUS LABS says Significant Visibility In Capex Likely For CDMO
30-Oct-2026 09:45:41
LAURUS LABS says Expanding Capabilities To Meet CDMO Mfg Needs
30-Oct-2026 09:45:19
LAURUS LABS says Partners Don't Want To Change Mfg Sites In CDMO
30-Oct-2026 09:44:50
Significant Visibility In Capex Likely For CDMO
30-Oct-2026 08:22:14
• FY27 EBITDA Margin Guidance: Management reiterated guidance of above 30% EBITDA margin and above 60% gross margin, despite Q2 EBITDA margin reaching 34.5%. •…
30-Oct-2026 07:59:52
• Kotak maintains Sell rating on Laurus Labs with a target price of ₹1,400. • Expects EBITDA CAGR of approximately 34% over FY26–29, with EBITDA margins reachi…
30-Oct-2026 07:48:20
• Jefferies maintains Hold rating on Laurus Labs and raises target price to ₹2,100 from ₹1,700. • Q2 revenue grows 33% YoY, while EBITDA surges 86% YoY, with E…
30-Oct-2026 07:46:09
• Goldman Sachs maintains Sell rating on Laurus Labs but raises target price to ₹1,600 from ₹1,425. • Q2 revenue grows 33% YoY, while EBITDA surges 86% YoY, wi…
29-Oct-2026 22:49:12
REVENUE UP 9% AT ₹2,206 CR (QOQ), UP 33% (YOY) EBITDA UP 18% AT ₹750 CR (QOQ), UP 86% (YOY) MARGINS AT 34.0% VS 31.5% (QOQ), 24.4% (YOY)
14-Oct-2026 20:09:04
• Company invested ₹107.8 Cr (INR 1,078,000,000) in KRKA Pharma Private Limited, a joint venture with KRKA d.d., Novo mesto, Slovenia • Acquired 10.78 Cr (107,…
13-Oct-2026 16:46:14
Board to consider un-audited results for quarter and half-year ended September 30, 2026. Also to consider interim dividend for FY 2026-27 and fixation of recor…
06-Oct-2026 18:09:07
• Company invested INR 12,09,60,500 and acquired 1,20,96,050 equity shares of KRPL at face value of INR 10/- • Total holding in KRPL is 2,11,68,000 equity shar…